p cdc2 tyr15  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    p cdc2 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    p cdc2 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    p cdc2 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    anti p tyr15 cdc2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc anti p tyr15 cdc2
    Anti P Tyr15 Cdc2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p tyr15 cdc2/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p tyr15 cdc2 - by Bioz Stars, 2024-06
    96/100 stars

    Images

    anti p tyr15 cdc2 cdk1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti p tyr15 cdc2 cdk1
    Anti P Tyr15 Cdc2 Cdk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p tyr15 cdc2 cdk1/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p tyr15 cdc2 cdk1 - by Bioz Stars, 2024-06
    94/100 stars

    Images

    p cdk1 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc p cdk1 tyr15
    ( A ) In vitro <t>CDK1</t> activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.
    P Cdk1 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdk1 tyr15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdk1 tyr15 - by Bioz Stars, 2024-06
    96/100 stars

    Images

    1) Product Images from "ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models"

    Article Title: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI161544

    ( A ) In vitro CDK1 activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.
    Figure Legend Snippet: ( A ) In vitro CDK1 activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.

    Techniques Used: In Vitro, Activity Assay, Western Blot, Expressing

    ( A ) Analysis of correlations between CDK1 expression levels and those of WEE1, PKMYT1, and ODF2L using TCGA OV data. ( B ) Analysis of the endogenous interaction between ODF2L and PKMYT1 by reverse coimmunoprecipitation followed by immunoblotting. ( C and D ) Analysis of the interaction between CDK1 and PKMYT1 in ODF2L-knockdown EOC cells ( C ) and the interaction between CDK1 and ODF2L in PKMYT1 knockdown EOC cells ( D ) by immunoprecipitation of endogenous CDK1 followed by immunoblotting. ( E ) BRET assay for the binding of PKMYT1 and CDK1 (plasmid design strategy is shown on left) measured in the indicated cells transfected with Halo-tagged CDK1 and Nluc-tagged PKMYT1 in the absence or presence of ODF2L. ( F ) Analysis of the binding of CDK1 and PKMYT1 to the C-terminally, middle-range, and N-terminally truncated ODF2L by coimmunoprecipitation. The indicated cells were cotransfected with Myc-PKMYT1, CDK1-V5, or Flag-tagged truncated ODF2L domains. ( G and H ) Analysis of cell viability upon AZD1775 treatment with or without ODF2L knockdown upon overexpression of PKMYT1 ( G ) or knockdown of PKMYT1 ( H ). AZD1775 (A2780, 200 nM; SKOV3, 200 nM). Data are the mean ± SD from 3 technical replicates in E , G , and H . Data are representative of 2 ( B ), 2 ( C ), 2 ( D ), 3 ( E ), 2 ( F ), 2 ( G ), and 2 ( H ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in H . ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.
    Figure Legend Snippet: ( A ) Analysis of correlations between CDK1 expression levels and those of WEE1, PKMYT1, and ODF2L using TCGA OV data. ( B ) Analysis of the endogenous interaction between ODF2L and PKMYT1 by reverse coimmunoprecipitation followed by immunoblotting. ( C and D ) Analysis of the interaction between CDK1 and PKMYT1 in ODF2L-knockdown EOC cells ( C ) and the interaction between CDK1 and ODF2L in PKMYT1 knockdown EOC cells ( D ) by immunoprecipitation of endogenous CDK1 followed by immunoblotting. ( E ) BRET assay for the binding of PKMYT1 and CDK1 (plasmid design strategy is shown on left) measured in the indicated cells transfected with Halo-tagged CDK1 and Nluc-tagged PKMYT1 in the absence or presence of ODF2L. ( F ) Analysis of the binding of CDK1 and PKMYT1 to the C-terminally, middle-range, and N-terminally truncated ODF2L by coimmunoprecipitation. The indicated cells were cotransfected with Myc-PKMYT1, CDK1-V5, or Flag-tagged truncated ODF2L domains. ( G and H ) Analysis of cell viability upon AZD1775 treatment with or without ODF2L knockdown upon overexpression of PKMYT1 ( G ) or knockdown of PKMYT1 ( H ). AZD1775 (A2780, 200 nM; SKOV3, 200 nM). Data are the mean ± SD from 3 technical replicates in E , G , and H . Data are representative of 2 ( B ), 2 ( C ), 2 ( D ), 3 ( E ), 2 ( F ), 2 ( G ), and 2 ( H ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in H . ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Techniques Used: Expressing, Western Blot, Immunoprecipitation, Bioluminescence Resonance Energy Transfer, Binding Assay, Plasmid Preparation, Transfection, Over Expression

    ( A and B ) In vitro CDK1 activity, total ODF2L expression levels ( A ) and cell viability ( B ) were analyzed in AZD1775-treated EOC cells derived from the primary tumor tissue of 57 ovarian cancer patients. Patient 1 was used as a control for different batches and labeled blue. ( C and D ) Analysis of correlations between ODF2L expression levels and CDK1 activity ( C ) or cell viability ( D ) in AZD1775-treated primary EOC cells. ODF2L expression levels and CDK1 activity were measured by quantification of the blots in A using ImageJ software. ( E ) Effect of ODF2L expression levels on in vivo tumor growth of PDXs treated with AZD1775. Tumor tissue from patients 1, 5, and 10; patients 3 and 21; and patients 33 and 36 were chosen for the xenograft on the basis of the differential expression levels of ODF2L in the primary cells confirmed by Western blotting. Mice were evenly grouped when the volume of their tumors reached approximately 100 mm 3 25 days after xenografting and were treated with vehicle or AZD1775 (40 mg/kg, orally, once per day). ID, identification. Data are representative of 2 ( A ) and 3 ( B ) independent biological experiments and represent the mean ± SD of 3 technical replicates of each sample ( B ). Error bars in E represent the SEM for tumor volume ( n = 6). ** P < 0.01 and *** P < 0.0001, by 2-tailed Pearson’s correlation coefficient ( C and D ), 2-way ANOVA for tumor volume ( E ), and 1-way ANOVA for tumor weight ( F ).
    Figure Legend Snippet: ( A and B ) In vitro CDK1 activity, total ODF2L expression levels ( A ) and cell viability ( B ) were analyzed in AZD1775-treated EOC cells derived from the primary tumor tissue of 57 ovarian cancer patients. Patient 1 was used as a control for different batches and labeled blue. ( C and D ) Analysis of correlations between ODF2L expression levels and CDK1 activity ( C ) or cell viability ( D ) in AZD1775-treated primary EOC cells. ODF2L expression levels and CDK1 activity were measured by quantification of the blots in A using ImageJ software. ( E ) Effect of ODF2L expression levels on in vivo tumor growth of PDXs treated with AZD1775. Tumor tissue from patients 1, 5, and 10; patients 3 and 21; and patients 33 and 36 were chosen for the xenograft on the basis of the differential expression levels of ODF2L in the primary cells confirmed by Western blotting. Mice were evenly grouped when the volume of their tumors reached approximately 100 mm 3 25 days after xenografting and were treated with vehicle or AZD1775 (40 mg/kg, orally, once per day). ID, identification. Data are representative of 2 ( A ) and 3 ( B ) independent biological experiments and represent the mean ± SD of 3 technical replicates of each sample ( B ). Error bars in E represent the SEM for tumor volume ( n = 6). ** P < 0.01 and *** P < 0.0001, by 2-tailed Pearson’s correlation coefficient ( C and D ), 2-way ANOVA for tumor volume ( E ), and 1-way ANOVA for tumor weight ( F ).

    Techniques Used: In Vitro, Activity Assay, Expressing, Derivative Assay, Labeling, Software, In Vivo, Western Blot

    ( A ) Schematic illustration of targeted LNP against ovarian ID8 cells using the ASSET platform (upper panel) and experimental design (lower panel). ( B and C ) Effect of combination treatment with siODF2L-LNP and AZD1775 on ID8 tumor growth. In vivo bioluminescence image ( B ) and average photonic flux ( C ) at week 7. LNPs (0.75 mg/kg, twice a week); AZD1775 (30 mg/kg, orally, once per day). n = 10. ( D ) Survival curves of ID8-bearing mice in the indicated groups. n = 10. ( E ) Quantification of peritoneal ID8 tumor nodule numbers in mice at the endpoint. ( F and G ) In vitro CDK1 activity and total ODF2L expression levels were analyzed by Western blotting ( F ), and the level of the DNA damage marker γH2AX was analyzed ( G ) by flow cytometry in the 2 or 3 ID8 tumors harvested from mice in each group at the endpoint. Data represent the mean ± SD; n = 10 ( B – E ). Data are the mean ± SD; n = 2 or n = 3 ( G ). Data are representative of 2 ( F ) and 3 ( G ) independent biological experiments. ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.
    Figure Legend Snippet: ( A ) Schematic illustration of targeted LNP against ovarian ID8 cells using the ASSET platform (upper panel) and experimental design (lower panel). ( B and C ) Effect of combination treatment with siODF2L-LNP and AZD1775 on ID8 tumor growth. In vivo bioluminescence image ( B ) and average photonic flux ( C ) at week 7. LNPs (0.75 mg/kg, twice a week); AZD1775 (30 mg/kg, orally, once per day). n = 10. ( D ) Survival curves of ID8-bearing mice in the indicated groups. n = 10. ( E ) Quantification of peritoneal ID8 tumor nodule numbers in mice at the endpoint. ( F and G ) In vitro CDK1 activity and total ODF2L expression levels were analyzed by Western blotting ( F ), and the level of the DNA damage marker γH2AX was analyzed ( G ) by flow cytometry in the 2 or 3 ID8 tumors harvested from mice in each group at the endpoint. Data represent the mean ± SD; n = 10 ( B – E ). Data are the mean ± SD; n = 2 or n = 3 ( G ). Data are representative of 2 ( F ) and 3 ( G ) independent biological experiments. ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Techniques Used: In Vivo, In Vitro, Activity Assay, Expressing, Western Blot, Marker, Flow Cytometry

    p cdc2 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    96/100 stars

    Images

    p cdc 2 tyr15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc p cdc 2 tyr15
    P Cdc 2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc 2 tyr15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc 2 tyr15 - by Bioz Stars, 2024-06
    96/100 stars

    Images

    p cdc2 y15  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc p cdc2 y15
    Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and <t>CDK1</t> signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.
    P Cdc2 Y15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 y15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 y15 - by Bioz Stars, 2024-06
    96/100 stars

    Images

    1) Product Images from "Identification of WEE1 as a target to make AKT inhibition more effective in melanoma"

    Article Title: Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

    Journal: Cancer Biology & Therapy

    doi: 10.1080/15384047.2017.1360446

    Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and CDK1 signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.
    Figure Legend Snippet: Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and CDK1 signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.

    Techniques Used:

    Diagram showing the mechanism of synergism for co-targeting AKT and WEE1 signaling pathways. Inhibition of siWEE1 (1) suppresses inhibitory phosphorylation of CDK1 leading to early-G2/M progression. This leads DNA damage (2) and activates p53 signaling. p53 inhibits cell cycle progression by induction of p21, allowing DNA damage repair. If the DNA damage is not repairable, p53 induces apoptosis. However, in many cancer cells, apoptotic cascades are suppressed by oncogenic alterations. Over-activated AKT inhibits pro-apoptotic factors while inducing antiapoptotic factors (3). AKT signaling also enhances cell cycle progression by CyclinD1 mediated phosphorylation of RB (4) and inhibition of p27 (5). Furthermore, AKT phosphorylates and induces Polo-like kinase 1 (PLK1) (6), which in turn inhibits pro-apoptotic functions of p53 and its family members, p63 and p73 (7). In addition, PLK1 also induces FOXM1 activity and M-phase progression (8). Proteins that were validated by Western blotting are shown in bold.
    Figure Legend Snippet: Diagram showing the mechanism of synergism for co-targeting AKT and WEE1 signaling pathways. Inhibition of siWEE1 (1) suppresses inhibitory phosphorylation of CDK1 leading to early-G2/M progression. This leads DNA damage (2) and activates p53 signaling. p53 inhibits cell cycle progression by induction of p21, allowing DNA damage repair. If the DNA damage is not repairable, p53 induces apoptosis. However, in many cancer cells, apoptotic cascades are suppressed by oncogenic alterations. Over-activated AKT inhibits pro-apoptotic factors while inducing antiapoptotic factors (3). AKT signaling also enhances cell cycle progression by CyclinD1 mediated phosphorylation of RB (4) and inhibition of p27 (5). Furthermore, AKT phosphorylates and induces Polo-like kinase 1 (PLK1) (6), which in turn inhibits pro-apoptotic functions of p53 and its family members, p63 and p73 (7). In addition, PLK1 also induces FOXM1 activity and M-phase progression (8). Proteins that were validated by Western blotting are shown in bold.

    Techniques Used: Inhibition, Activity Assay, Western Blot

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc p cdc2 tyr15
    P Cdc2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 tyr15/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 tyr15 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti p tyr15 cdc2
    Anti P Tyr15 Cdc2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p tyr15 cdc2/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p tyr15 cdc2 - by Bioz Stars, 2024-06
    96/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti p tyr15 cdc2 cdk1
    Anti P Tyr15 Cdc2 Cdk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p tyr15 cdc2 cdk1/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p tyr15 cdc2 cdk1 - by Bioz Stars, 2024-06
    94/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc p cdk1 tyr15
    ( A ) In vitro <t>CDK1</t> activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.
    P Cdk1 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdk1 tyr15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdk1 tyr15 - by Bioz Stars, 2024-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc p cdc 2 tyr15
    ( A ) In vitro <t>CDK1</t> activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.
    P Cdc 2 Tyr15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc 2 tyr15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc 2 tyr15 - by Bioz Stars, 2024-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc p cdc2 y15
    Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and <t>CDK1</t> signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.
    P Cdc2 Y15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p cdc2 y15/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p cdc2 y15 - by Bioz Stars, 2024-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) In vitro CDK1 activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.

    Journal: The Journal of Clinical Investigation

    Article Title: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

    doi: 10.1172/JCI161544

    Figure Lengend Snippet: ( A ) In vitro CDK1 activity (top2 plots) was analyzed in EOC cells with or without ODF2L knockdown and then treated with DMSO or AZD1775 (treatment: DMSO/200 nM AZD1775, 4 hours). ( B ) Immunoblots of the T14 and Y15 phosphorylation status of CDK1 in the indicated EOC cells (treatment: DMSO/200 nM AZD1775, 24 hours). ( C and D ) In vitro CDK1 activity (top 2 plots) was analyzed in CDK1 T14A–expressing ( C ), CDK1 Y15F–expressing ( D ), and CDK1 WT–expressing ( C and D ) EOC cells with endogenous CDK1 removed (treatment: DMSO or 200 nM AZD1775 for 4 hours). ( E and F ) Representative images and quantification of colony formation ( E ) and apoptotic cell death ( F ) of EOC cells with or without ODF2L knockdown. Cells were treated with sublethal doses of AZD1775 (A2780, 200 nM; SKOV3, 200 nM) together with or without 5 μM Ro-3306 for 72 hours. Data are the mean ± SD from 3 technical replicates of each sample and are representative of 3 ( A ), 2 ( B ), and 3 ( C – F ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in A – D . *** P < 0.001 and **** P < 0.0001, by 1-way ANOVA.

    Article Snippet: In the immunoblots using the whole-cell lysate, antibodies against p-ATM (Ser1981) (catalog 5883); ATM (catalog 2873); p-CHK2 (Thr68) (catalog 2197), CHK2 (catalog 6334); p-RPA32/RPA2 S8 (catalog 83745); RPA32/RPA2 (catalog 35869); p-CDK1 (Tyr15) (catalog 4539); p-CDK1 T14 (catalog 2543); CDK1 (catalog 77055); p–histone γH2AX (Ser139) (catalog 9718); and PKMYT1 (catalog 4282) were all obtained from Cell Signaling Technology.

    Techniques: In Vitro, Activity Assay, Western Blot, Expressing

    ( A ) Analysis of correlations between CDK1 expression levels and those of WEE1, PKMYT1, and ODF2L using TCGA OV data. ( B ) Analysis of the endogenous interaction between ODF2L and PKMYT1 by reverse coimmunoprecipitation followed by immunoblotting. ( C and D ) Analysis of the interaction between CDK1 and PKMYT1 in ODF2L-knockdown EOC cells ( C ) and the interaction between CDK1 and ODF2L in PKMYT1 knockdown EOC cells ( D ) by immunoprecipitation of endogenous CDK1 followed by immunoblotting. ( E ) BRET assay for the binding of PKMYT1 and CDK1 (plasmid design strategy is shown on left) measured in the indicated cells transfected with Halo-tagged CDK1 and Nluc-tagged PKMYT1 in the absence or presence of ODF2L. ( F ) Analysis of the binding of CDK1 and PKMYT1 to the C-terminally, middle-range, and N-terminally truncated ODF2L by coimmunoprecipitation. The indicated cells were cotransfected with Myc-PKMYT1, CDK1-V5, or Flag-tagged truncated ODF2L domains. ( G and H ) Analysis of cell viability upon AZD1775 treatment with or without ODF2L knockdown upon overexpression of PKMYT1 ( G ) or knockdown of PKMYT1 ( H ). AZD1775 (A2780, 200 nM; SKOV3, 200 nM). Data are the mean ± SD from 3 technical replicates in E , G , and H . Data are representative of 2 ( B ), 2 ( C ), 2 ( D ), 3 ( E ), 2 ( F ), 2 ( G ), and 2 ( H ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in H . ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Journal: The Journal of Clinical Investigation

    Article Title: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

    doi: 10.1172/JCI161544

    Figure Lengend Snippet: ( A ) Analysis of correlations between CDK1 expression levels and those of WEE1, PKMYT1, and ODF2L using TCGA OV data. ( B ) Analysis of the endogenous interaction between ODF2L and PKMYT1 by reverse coimmunoprecipitation followed by immunoblotting. ( C and D ) Analysis of the interaction between CDK1 and PKMYT1 in ODF2L-knockdown EOC cells ( C ) and the interaction between CDK1 and ODF2L in PKMYT1 knockdown EOC cells ( D ) by immunoprecipitation of endogenous CDK1 followed by immunoblotting. ( E ) BRET assay for the binding of PKMYT1 and CDK1 (plasmid design strategy is shown on left) measured in the indicated cells transfected with Halo-tagged CDK1 and Nluc-tagged PKMYT1 in the absence or presence of ODF2L. ( F ) Analysis of the binding of CDK1 and PKMYT1 to the C-terminally, middle-range, and N-terminally truncated ODF2L by coimmunoprecipitation. The indicated cells were cotransfected with Myc-PKMYT1, CDK1-V5, or Flag-tagged truncated ODF2L domains. ( G and H ) Analysis of cell viability upon AZD1775 treatment with or without ODF2L knockdown upon overexpression of PKMYT1 ( G ) or knockdown of PKMYT1 ( H ). AZD1775 (A2780, 200 nM; SKOV3, 200 nM). Data are the mean ± SD from 3 technical replicates in E , G , and H . Data are representative of 2 ( B ), 2 ( C ), 2 ( D ), 3 ( E ), 2 ( F ), 2 ( G ), and 2 ( H ) independent biological experiments. Blots shown were run in parallel, contemporaneously using the same cell lysate harvested from 1 representative experiment for each cell line in H . ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Article Snippet: In the immunoblots using the whole-cell lysate, antibodies against p-ATM (Ser1981) (catalog 5883); ATM (catalog 2873); p-CHK2 (Thr68) (catalog 2197), CHK2 (catalog 6334); p-RPA32/RPA2 S8 (catalog 83745); RPA32/RPA2 (catalog 35869); p-CDK1 (Tyr15) (catalog 4539); p-CDK1 T14 (catalog 2543); CDK1 (catalog 77055); p–histone γH2AX (Ser139) (catalog 9718); and PKMYT1 (catalog 4282) were all obtained from Cell Signaling Technology.

    Techniques: Expressing, Western Blot, Immunoprecipitation, Bioluminescence Resonance Energy Transfer, Binding Assay, Plasmid Preparation, Transfection, Over Expression

    ( A and B ) In vitro CDK1 activity, total ODF2L expression levels ( A ) and cell viability ( B ) were analyzed in AZD1775-treated EOC cells derived from the primary tumor tissue of 57 ovarian cancer patients. Patient 1 was used as a control for different batches and labeled blue. ( C and D ) Analysis of correlations between ODF2L expression levels and CDK1 activity ( C ) or cell viability ( D ) in AZD1775-treated primary EOC cells. ODF2L expression levels and CDK1 activity were measured by quantification of the blots in A using ImageJ software. ( E ) Effect of ODF2L expression levels on in vivo tumor growth of PDXs treated with AZD1775. Tumor tissue from patients 1, 5, and 10; patients 3 and 21; and patients 33 and 36 were chosen for the xenograft on the basis of the differential expression levels of ODF2L in the primary cells confirmed by Western blotting. Mice were evenly grouped when the volume of their tumors reached approximately 100 mm 3 25 days after xenografting and were treated with vehicle or AZD1775 (40 mg/kg, orally, once per day). ID, identification. Data are representative of 2 ( A ) and 3 ( B ) independent biological experiments and represent the mean ± SD of 3 technical replicates of each sample ( B ). Error bars in E represent the SEM for tumor volume ( n = 6). ** P < 0.01 and *** P < 0.0001, by 2-tailed Pearson’s correlation coefficient ( C and D ), 2-way ANOVA for tumor volume ( E ), and 1-way ANOVA for tumor weight ( F ).

    Journal: The Journal of Clinical Investigation

    Article Title: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

    doi: 10.1172/JCI161544

    Figure Lengend Snippet: ( A and B ) In vitro CDK1 activity, total ODF2L expression levels ( A ) and cell viability ( B ) were analyzed in AZD1775-treated EOC cells derived from the primary tumor tissue of 57 ovarian cancer patients. Patient 1 was used as a control for different batches and labeled blue. ( C and D ) Analysis of correlations between ODF2L expression levels and CDK1 activity ( C ) or cell viability ( D ) in AZD1775-treated primary EOC cells. ODF2L expression levels and CDK1 activity were measured by quantification of the blots in A using ImageJ software. ( E ) Effect of ODF2L expression levels on in vivo tumor growth of PDXs treated with AZD1775. Tumor tissue from patients 1, 5, and 10; patients 3 and 21; and patients 33 and 36 were chosen for the xenograft on the basis of the differential expression levels of ODF2L in the primary cells confirmed by Western blotting. Mice were evenly grouped when the volume of their tumors reached approximately 100 mm 3 25 days after xenografting and were treated with vehicle or AZD1775 (40 mg/kg, orally, once per day). ID, identification. Data are representative of 2 ( A ) and 3 ( B ) independent biological experiments and represent the mean ± SD of 3 technical replicates of each sample ( B ). Error bars in E represent the SEM for tumor volume ( n = 6). ** P < 0.01 and *** P < 0.0001, by 2-tailed Pearson’s correlation coefficient ( C and D ), 2-way ANOVA for tumor volume ( E ), and 1-way ANOVA for tumor weight ( F ).

    Article Snippet: In the immunoblots using the whole-cell lysate, antibodies against p-ATM (Ser1981) (catalog 5883); ATM (catalog 2873); p-CHK2 (Thr68) (catalog 2197), CHK2 (catalog 6334); p-RPA32/RPA2 S8 (catalog 83745); RPA32/RPA2 (catalog 35869); p-CDK1 (Tyr15) (catalog 4539); p-CDK1 T14 (catalog 2543); CDK1 (catalog 77055); p–histone γH2AX (Ser139) (catalog 9718); and PKMYT1 (catalog 4282) were all obtained from Cell Signaling Technology.

    Techniques: In Vitro, Activity Assay, Expressing, Derivative Assay, Labeling, Software, In Vivo, Western Blot

    ( A ) Schematic illustration of targeted LNP against ovarian ID8 cells using the ASSET platform (upper panel) and experimental design (lower panel). ( B and C ) Effect of combination treatment with siODF2L-LNP and AZD1775 on ID8 tumor growth. In vivo bioluminescence image ( B ) and average photonic flux ( C ) at week 7. LNPs (0.75 mg/kg, twice a week); AZD1775 (30 mg/kg, orally, once per day). n = 10. ( D ) Survival curves of ID8-bearing mice in the indicated groups. n = 10. ( E ) Quantification of peritoneal ID8 tumor nodule numbers in mice at the endpoint. ( F and G ) In vitro CDK1 activity and total ODF2L expression levels were analyzed by Western blotting ( F ), and the level of the DNA damage marker γH2AX was analyzed ( G ) by flow cytometry in the 2 or 3 ID8 tumors harvested from mice in each group at the endpoint. Data represent the mean ± SD; n = 10 ( B – E ). Data are the mean ± SD; n = 2 or n = 3 ( G ). Data are representative of 2 ( F ) and 3 ( G ) independent biological experiments. ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Journal: The Journal of Clinical Investigation

    Article Title: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

    doi: 10.1172/JCI161544

    Figure Lengend Snippet: ( A ) Schematic illustration of targeted LNP against ovarian ID8 cells using the ASSET platform (upper panel) and experimental design (lower panel). ( B and C ) Effect of combination treatment with siODF2L-LNP and AZD1775 on ID8 tumor growth. In vivo bioluminescence image ( B ) and average photonic flux ( C ) at week 7. LNPs (0.75 mg/kg, twice a week); AZD1775 (30 mg/kg, orally, once per day). n = 10. ( D ) Survival curves of ID8-bearing mice in the indicated groups. n = 10. ( E ) Quantification of peritoneal ID8 tumor nodule numbers in mice at the endpoint. ( F and G ) In vitro CDK1 activity and total ODF2L expression levels were analyzed by Western blotting ( F ), and the level of the DNA damage marker γH2AX was analyzed ( G ) by flow cytometry in the 2 or 3 ID8 tumors harvested from mice in each group at the endpoint. Data represent the mean ± SD; n = 10 ( B – E ). Data are the mean ± SD; n = 2 or n = 3 ( G ). Data are representative of 2 ( F ) and 3 ( G ) independent biological experiments. ** P < 0.01, *** P < 0.001, and **** P < 0.0001, by 1-way ANOVA.

    Article Snippet: In the immunoblots using the whole-cell lysate, antibodies against p-ATM (Ser1981) (catalog 5883); ATM (catalog 2873); p-CHK2 (Thr68) (catalog 2197), CHK2 (catalog 6334); p-RPA32/RPA2 S8 (catalog 83745); RPA32/RPA2 (catalog 35869); p-CDK1 (Tyr15) (catalog 4539); p-CDK1 T14 (catalog 2543); CDK1 (catalog 77055); p–histone γH2AX (Ser139) (catalog 9718); and PKMYT1 (catalog 4282) were all obtained from Cell Signaling Technology.

    Techniques: In Vivo, In Vitro, Activity Assay, Expressing, Western Blot, Marker, Flow Cytometry

    Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and CDK1 signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.

    Journal: Cancer Biology & Therapy

    Article Title: Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

    doi: 10.1080/15384047.2017.1360446

    Figure Lengend Snippet: Targeting AKT3 and WEE1 increased p53 while reducing FOXM1 and CDK1 signaling. (A) and (B). Knockdown of WEE1 kinase led to a dose-dependent decrease in the phosphorylation of its substrate CDK1. Dose-dependent increase in the phosphorylation of H2AX was observed. Consequently, this resulted in increased p53, p21 as well as p27 levels, which are known to be inhibitory to cell proliferation. ERK2 served as a control for equal protein loading.

    Article Snippet: Primary antibodies used: p21 (sc-756), p27 (sc-528), p53 (sc-6243) and ERK2 (sc-1647) from Santa Cruz Biotechnology (Dallas, TX), pAKT (9271), AKT3 (3788), Total AKT (4685), pWEE1 (4910), WEE1 (4936), p-CDC2 (Y15) (9111), pRB (S807/811) (9308), pRB (S795) (9301), pRB (S780) (9307), (9309) and p-Histone H2AX (S139) (2577) from Cell Signaling (Danvers, MA).

    Techniques:

    Diagram showing the mechanism of synergism for co-targeting AKT and WEE1 signaling pathways. Inhibition of siWEE1 (1) suppresses inhibitory phosphorylation of CDK1 leading to early-G2/M progression. This leads DNA damage (2) and activates p53 signaling. p53 inhibits cell cycle progression by induction of p21, allowing DNA damage repair. If the DNA damage is not repairable, p53 induces apoptosis. However, in many cancer cells, apoptotic cascades are suppressed by oncogenic alterations. Over-activated AKT inhibits pro-apoptotic factors while inducing antiapoptotic factors (3). AKT signaling also enhances cell cycle progression by CyclinD1 mediated phosphorylation of RB (4) and inhibition of p27 (5). Furthermore, AKT phosphorylates and induces Polo-like kinase 1 (PLK1) (6), which in turn inhibits pro-apoptotic functions of p53 and its family members, p63 and p73 (7). In addition, PLK1 also induces FOXM1 activity and M-phase progression (8). Proteins that were validated by Western blotting are shown in bold.

    Journal: Cancer Biology & Therapy

    Article Title: Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

    doi: 10.1080/15384047.2017.1360446

    Figure Lengend Snippet: Diagram showing the mechanism of synergism for co-targeting AKT and WEE1 signaling pathways. Inhibition of siWEE1 (1) suppresses inhibitory phosphorylation of CDK1 leading to early-G2/M progression. This leads DNA damage (2) and activates p53 signaling. p53 inhibits cell cycle progression by induction of p21, allowing DNA damage repair. If the DNA damage is not repairable, p53 induces apoptosis. However, in many cancer cells, apoptotic cascades are suppressed by oncogenic alterations. Over-activated AKT inhibits pro-apoptotic factors while inducing antiapoptotic factors (3). AKT signaling also enhances cell cycle progression by CyclinD1 mediated phosphorylation of RB (4) and inhibition of p27 (5). Furthermore, AKT phosphorylates and induces Polo-like kinase 1 (PLK1) (6), which in turn inhibits pro-apoptotic functions of p53 and its family members, p63 and p73 (7). In addition, PLK1 also induces FOXM1 activity and M-phase progression (8). Proteins that were validated by Western blotting are shown in bold.

    Article Snippet: Primary antibodies used: p21 (sc-756), p27 (sc-528), p53 (sc-6243) and ERK2 (sc-1647) from Santa Cruz Biotechnology (Dallas, TX), pAKT (9271), AKT3 (3788), Total AKT (4685), pWEE1 (4910), WEE1 (4936), p-CDC2 (Y15) (9111), pRB (S807/811) (9308), pRB (S795) (9301), pRB (S780) (9307), (9309) and p-Histone H2AX (S139) (2577) from Cell Signaling (Danvers, MA).

    Techniques: Inhibition, Activity Assay, Western Blot